Samuel Der Sarkissian
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Samuel Der Sarkissian has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Artiene Tatian
School of Clinical Medicine, University of New South Wales
2 shared publications - Geoffrey D. Cains
University of New South Wales Sydney New South Wales Australia
2 shared publications - John Walter Frew
Department of Dermatology Liverpool Hospital Liverpool New South Wales Australia
2 shared publications - Chun Wie Chong
School of Pharmacy, Monash University Malaysia, Subang Jaya, Malaysia
1 shared publication - Eliana Mariño
ImmunoBiota Therapeutics Pty Ltd., Melbourne 3187, Australia
1 shared publication - Haady Fallah
Concord Repatriation General Hospital New South Wales Australia
1 shared publication
Latest Publications
- 4 September 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (8) , 492-494
Superficial Granulomatous Pyoderma: A Case Report With Diffuse Cutaneous Involvement and a Systematic Review of the Literature
- 4 September 2025
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 66 (8) , 492-494
Superficial Granulomatous Pyoderma: A Case Report With Diffuse Cutaneous Involvement and a Systematic Review of the Literature
- Open Access
- 31 December 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 188 (5) , 673-675
The association between pilonidal sinus disease and hidradenitis suppurativa: a systematic review and meta-analysis
We performed a systematic review and meta-analysis examining the association between hidradenitis suppurativa (HS) and pilonidal sinus disease (PSD). We found a strong association between HS and PSD, with an increased occurrence of PSD in individuals with HS compared with unaffected controls. Given this strong association, patients with HS should be assessed for PSD.
- 31 December 2022
- Published by Oxford University Press (OUP) in British Journal of Dermatology
- Vol. 188 (5) , 673-675
Open AccessThe association between pilonidal sinus disease and hidradenitis suppurativa: a systematic review and meta-analysis
We performed a systematic review and meta-analysis examining the association between hidradenitis suppurativa (HS) and pilonidal sinus disease (PSD). We found a strong association between HS and PSD, with an increased occurrence of PSD in individuals with HS compared with unaffected controls. Given this strong association, patients with HS should be assessed for PSD.
- Open Access
- 30 August 2022
- Published by Wiley in Experimental Dermatology
- Vol. 31 (12) , 1872-1880
Adalimumab therapy is associated with increased faecal short chain fatty acids in hidradenitis suppurativa
Altered gut microbiota composition has been observed in individuals with hidradenitis suppurutiva (HS) and many other inflammatory diseases, including obesity, type 1 and type 2 diabetes. Here, we addressed whether adalimumab, a systemic anti‐inflammatory therapy, may impact the microbiota biochemical profile, particularly on beneficial metabolites such as short‐chain fatty acids (SCFAs). We conducted an observational single‐arm pilot trial to assess gut microbiota composition by 16S rRNA gene sequence analysis and to detect metabolite signatures by gas chromatography in stool samples from participants with HS prior to and 12 weeks after commencing adalimumab therapy. HS individuals that better responded to adalimumab treatment showed a shift in the composition and function of the gut microbiota with significantly increased SCFA acetate and propionate compared to age, gender and BMI‐matched healthy controls. A positive correlation was observed between propionate with Prevotella sp and Faecalibacterium prausnitsii. Increased SCFAs, changes in gut microbiota composition, function and metabolic profile following 12 weeks of adalimumab suggest that targeting SCFAs may be considered a potential biomarker to be evaluated as a complementary protective factor or as a diagnostically relevant signal in HS.
- 30 August 2022
- Published by Wiley in Experimental Dermatology
- Vol. 31 (12) , 1872-1880
Open AccessAdalimumab therapy is associated with increased faecal short chain fatty acids in hidradenitis suppurativa
Altered gut microbiota composition has been observed in individuals with hidradenitis suppurutiva (HS) and many other inflammatory diseases, including obesity, type 1 and type 2 diabetes. Here, we addressed whether adalimumab, a systemic anti‐inflammatory therapy, may impact the microbiota biochemical profile, particularly on beneficial metabolites such as short‐chain fatty acids (SCFAs). We conducted an observational single‐arm pilot trial to assess gut microbiota composition by 16S rRNA gene sequence analysis and to detect metabolite signatures by gas chromatography in stool samples from participants with HS prior to and 12 weeks after commencing adalimumab therapy. HS individuals that better responded to adalimumab treatment showed a shift in the composition and function of the gut microbiota with significantly increased SCFA acetate and propionate compared to age, gender and BMI‐matched healthy controls. A positive correlation was observed between propionate with Prevotella sp and Faecalibacterium prausnitsii. Increased SCFAs, changes in gut microbiota composition, function and metabolic profile following 12 weeks of adalimumab suggest that targeting SCFAs may be considered a potential biomarker to be evaluated as a complementary protective factor or as a diagnostically relevant signal in HS.
- 24 May 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , 360-363
Ultrasound‐guided de‐roofing of epithelialised tunnels of hidradenitis suppurativa
Hidradenitis Suppurativa is a chronic inflammatory disease manifesting in painful nodules, abscesses and malodorous draining tunnels with a pre‐disposition to flexural regions of skin. Traditional surgical interventions include excision of clinically visible lesions and in severe cases – excision down to fascia of entire anatomical regions (axilla, groin) and repair with split‐thickness grafting or skin substitutes. However, such techniques are plagued by long healing times (up to several months), extensive tissue loss and high recurrence rates given that a large proportion of disease is not clinically visible. Deroofing is a tissue‐saving surgical technique, ideal for Hurley Stage 2 disease, which when combined with bedside pre‐operative sonography can allow for the accurate identification and removal of occult dermal tunnels whilst minimising the risks of pain, infection, minimising healing times and can be safely conducted in the setting of immunomodulatory therapy.
- 24 May 2021
- Published by Wiley in Australasian Journal of Dermatology
- Vol. 62 (3) , 360-363
Ultrasound‐guided de‐roofing of epithelialised tunnels of hidradenitis suppurativa
Hidradenitis Suppurativa is a chronic inflammatory disease manifesting in painful nodules, abscesses and malodorous draining tunnels with a pre‐disposition to flexural regions of skin. Traditional surgical interventions include excision of clinically visible lesions and in severe cases – excision down to fascia of entire anatomical regions (axilla, groin) and repair with split‐thickness grafting or skin substitutes. However, such techniques are plagued by long healing times (up to several months), extensive tissue loss and high recurrence rates given that a large proportion of disease is not clinically visible. Deroofing is a tissue‐saving surgical technique, ideal for Hurley Stage 2 disease, which when combined with bedside pre‐operative sonography can allow for the accurate identification and removal of occult dermal tunnels whilst minimising the risks of pain, infection, minimising healing times and can be safely conducted in the setting of immunomodulatory therapy.